Aminazin (chlorpromazine) coated tablets 25 mg. №20

active ingredient : 1 tablet contains chlorpromazine hydrochloride 25 mg;

excipients: calcium hydrogen phosphate, microcrystalline cellulose, potato starch, colloidal silicon dioxide, calcium stearate, stearic acid, polyethylene glycol 4000, talc, hypromellose, titanium dioxide (E 171), dye sunset yellow FCF (E 110).

Coated tablets.

Basic physical and chemical properties : film-coated tablets, from yellow to light orange, biconvex. The previous section shows two layers.

Antipsychotics. Chlorpromazine. ATX code N05A A01.

Antipsychotic, neuroleptic, sedative, muscle relaxant, antiemetic. Shows a blocking effect on dopaminergic and adrenergic receptors. The main feature of the drug is the combination of antipsychotic action with the ability to influence the emotional sphere.

The mechanism of antipsychotic action is due to the blocking of postsynaptic dopamine receptors in the mesolimbic structures of the brain. As a result, delusions and hallucinations are weakened or completely eliminated, psychomotor agitation is stopped, affective reactions, anxiety, anxiety are reduced, motor activity is reduced. Due to the blockade of dopamine receptors, the secretion of prolactin by the pituitary gland increases.

By blocking α-adrenergic receptors, chlorpromazine exhibits a pronounced sedative effect. The presence of a strong sedative effect is one of the main features of chlorpromazine in comparison with other antipsychotics.

The general calming effect is combined with the inhibition of conditioned reflex activity and, above all, motor-defensive reflexes, a decrease in spontaneous motor activity, relaxation of skeletal muscles, and a decrease in reactivity to endogenous and exogenous stimuli while maintaining consciousness.

Shows a pronounced central and peripheral antiemetic effect; the central effect is due to the inhibition or blockade of dopamine D2 receptors in the chemoreceptor trigger zone of the cerebellum, the peripheral effect is due to blockade of the vagus nerve in the gastrointestinal tract. The antiemetic effect is enhanced by the anticholinergic, sedative and antihistamine properties of chlorpromazine.

The anticholinergic effect is due to the competitive blockade of M-cholinergic receptors; anxiolytic, sedative and analgesic – weakening of excitation in the reticular formation of the brain stem.

Moderately reduces the severity of the inflammatory reaction, reduces vascular permeability, reduces the activity of kinins and hyaluronidase, and exhibits a weak antihistamine effect. Reduces systolic and diastolic blood pressure, causes tachycardia. It has pronounced cataleptogenic properties. Suppresses the release of hormones of the hypothalamus and pituitary gland (however, it increases the secretion of prolactin). Shows weak or moderate extrapyramidal action. Shows hypothermic action.

Potentiates the action of analgesics, local anesthetics, hypnotics and anticonvulsants.

Adults.Chronic paranoid and hallucinatory-paranoid states, states of psychomotor agitation in schizophrenia (hallucinatory-delusional, hebephrenic, catatonic syndromes), alcoholic psychosis, manic arousal in manic-depressive psychosis, mental disorders in epilepsy, agitated depression in patients with presenile psychosis, manic depressive psychosis, as well as other diseases accompanied by excitement, tension; neurological diseases accompanied by an increase in muscle tone Meniere’s disease, vomiting, treatment and prevention of vomiting in the treatment of antitumor agents and radiation therapy prolonged hiccups; itchy dermatoses as part of complex therapy: persistent pain, including causalgia (in combination with analgesics),

Children. Schizophrenia, autism.

Hypersensitivity to chlorpromazine and other components of the drug; severe violations of the liver (cirrhosis, hepatitis, hemolytic jaundice) and / or kidneys (nephritis, acute pyelitis, amyloidosis of the kidneys), hematopoietic organs; progressive systemic diseases of the brain and spinal cord (slow neuroinfections, for example, multiple sclerosis), gastric and duodenal ulcers during an exacerbation; myxedema; severe cardiovascular diseases (decompensated heart failure and heart defects, severe myocardial dystrophy, severe arterial hypotension, rheumatic heart disease in the late stages) thromboembolism; late stage of bronchiectasis; glaucoma; urinary retention due to prostatic hyperplasia stroke, acute period of traumatic brain injury; cholelithiasis and urolithiasis; acute infectious diseases; severe depression of the central nervous system, coma, brain injury, simultaneous use with barbiturates, alcohol, drugs.